Acasti Pharma appoints Don Olds to its Board as Independent Director

– CANADA, Laval – Acasti Pharma Inc. (NASDAQ:ACST / TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has appointed Donald Olds to its Board of Directors and Audit Committee.

“We are very pleased to welcome Don as a new independent director to Acasti’s Board and a member of our Audit Committee. His extensive experience in corporate development and raising capital in the healthcare sector will be valuable as we continue to advance development of our lead drug candidate and our partnering discussions in Asia and elsewhere,” said Roderick Carter, M.D., Chairman of Acasti Pharma.

“I welcome this opportunity to contribute to the progress of Acasti at this critical, late stage of development of its lead product candidate, CaPre. With the recent initiation of Phase 3 clinical trials in the U.S., Acasti is positioned to begin planning for commercial launch and securing value-building regional partnerships for CaPre, a treatment that may offer clinical benefits over existing therapies for patients afflicted with severe hypertriglyceridemia,” said Mr. Olds.

Mr. Olds is President and Chief Executive Officer of the NEOMED Institute, an R&D organization dedicated to advancing Canadian research discoveries to commercial success. Prior to NEOMED, he was the Chief Operating Officer of Telesta Therapeutics Inc., a TSX-listed biotechnology company, where he was responsible for finance and investor relations, manufacturing operations, business development, human resources and strategy. In 2016, he led the successful sale of Telesta to a larger public biotechnology company. Prior to Telesta, he was President and Chief Executive Officer of Presagia Corp., and Chief Financial Officer and Chief Operating Officer of Aegera Therapeutics, where he was responsible for clinical operations, business development, finance, and mergers and acquisitions. At both Telesta and Aegera, Mr. Olds was responsible for raising more than $100 million in equity financing and leading regional and global licensing transactions with life sciences companies.
Mr. Olds is currently Director of Goodfood Market Corp, Chairman of Oxfam Quebec and Director of Presagia Corp. He has extensive past corporate governance experience serving on the boards of private and public for-profit and not-for-profit organizations. He holds an MBA (Finance & Strategy) and M.Sc. (Renewable Resources) from McGill University.

With the appointment of Mr. Olds, Acasti regains compliance with the Nasdaq Listing Rule 5605(c) and and National Instrument 52-110 of the Canadian securities regulators, which require that a company’s Audit Committee be comprised of at least three independent directors.

About Acasti Pharma

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. CaPre is being evaluated in a Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that includes 3 to 4 million patients in the U.S. and may expand significantly if omega-3s demonstrate long-term cardiovascular benefits in on-going outcomes studies. Acasti’s strategy is to commercialize CaPre in the U.S. and the company is pursuing partnerships to market CaPre in major countries around the world.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.